Table 2 Intraoperative variables

From: Levosimendan for postoperative subclinical heart failure after noncardiac surgery: a randomized, double-blinded, phase III trial

 

Levosimendan

(n = 115)

Placebo

(n = 113)

p Value

Time of surgery, mean (SD)

241 (109)

233 (92)

0.536

Time of anesthesia, mean (SD)

283 (111)

278 (93)

0.730

Type of surgery, n (%)

General

65 (57)

75 (66)

0.211

Urology

49 (43)

37 (34)

0.162

Anesthetic management, mean (SD) if used

Propofol, mg

208 (251)

185 (253)

0.496

Fentanyl, µg

850 (460)

850 (450)

0.786

Phenylephrine, mg

0.4 (0.4)

0.3 (0.3)

0.166

Norepinephrine, mg

1.5 (1.5)

1.0 (0.9)

0.007

Fluids management, n (%) and mean (SD) if used

Crystalloids, mL

3190 (1435)

2740 (1305)

0.317

Albumin, n (%)

65 (56)

55 (48)

0.292

Albumin, mL

328 (377)

291 (284)

0.544

Blood transfusion, n (%)

25 (22)

22 (19)

0.795

Blood transfusion, mL

884 (430)

697 (466)

0.161

Blood loss, mL

1067 (950)

899 (839)

0.349

Urinary output, mL

500 (490)

534 (433)

0.631

Blood pressure, mean (SD)

TWA MAP, mmHg

77 (6)

80 (6)

0.001

TWA systole, mmHg

122 (12)

123 (12)

0.806

TWA diastole, mmHg

57 (7)

58 (6)

0.374

Hemodynamic, mean (SD)

TWA SV, mL

78 (31)

79 (39)

0.315

TWA CI, L

3.1 (4.9)

3.1 (4.6)

0.320

  1. Summary characteristics are presented as counts (percentages) of patients within group or means (standard deviations). p values are for two-sided T-tests or Chi-square or Fisher exact test, respectively. A p value < 0.095 was considered as statistically significant. Due to the exploratory character of these analysis, no correction for multiplicity was performed.
  2. TWA time-weighted average, MAP mean arterial pressure, SV stroke volume, CI cardiac index.